Related references
Note: Only part of the references are listed.Translational genomics of nasopharyngeal cancer
Chi Man Tsang et al.
SEMINARS IN CANCER BIOLOGY (2020)
Chemotherapy and CDK4/6 Inhibition in Cancer Treatment: Timing Is Everything
Anne Fassl et al.
CANCER CELL (2020)
mTORC2-mediated PDHE1α nuclear translocation links EBV-LMP1 reprogrammed glucose metabolism to cancer metastasis in nasopharyngeal carcinoma
Jun Zhang et al.
ONCOGENE (2019)
RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
Shukui Qin et al.
FUTURE ONCOLOGY (2019)
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Kamal Pandey et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Establishment of a nasopharyngeal carcinoma cell line capable of undergoing lytic Epstein-Barr virus reactivation
Yim Ling Yip et al.
LABORATORY INVESTIGATION (2018)
Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma
Chi-Hang Wong et al.
SCIENTIFIC REPORTS (2018)
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
Wenfeng Fang et al.
LANCET ONCOLOGY (2018)
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial
Baohui Han et al.
JAMA ONCOLOGY (2018)
Establishment and characterization of new tumor xenografts and cancer cell lines from EBV-positive nasopharyngeal carcinoma
Weitao Lin et al.
NATURE COMMUNICATIONS (2018)
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
Julien Bollard et al.
GUT (2017)
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C. Yang et al.
ONCOGENE (2017)
Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes
Li Zhang et al.
MOLECULAR CANCER RESEARCH (2017)
Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner
Feng-Shu Hsieh et al.
MOLECULAR ONCOLOGY (2017)
Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations
Yvonne Y. Li et al.
NATURE COMMUNICATIONS (2017)
An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma
Jessica L. F. Teh et al.
CANCER RESEARCH (2016)
A Landscape of Pharmacogenomic Interactions in Cancer
Francesco Iorio et al.
CELL (2016)
Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown
Mihaela Pertea et al.
NATURE PROTOCOLS (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma
Wei Dai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma
Hong Zheng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Clinical trials in nasopharyngeal carcinoma-past, present and future
Cheng Xu et al.
CHINESE CLINICAL ONCOLOGY (2016)
CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity
Chenyi Yang et al.
CANCER RESEARCH (2015)
HISAT: a fast spliced aligner with low memory requirements
Daehwan Kim et al.
NATURE METHODS (2015)
Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway
Ge Qin et al.
ONCOTARGET (2015)
Autophagy, cell death, and cancer
Lin Lin et al.
MOLECULAR & CELLULAR ONCOLOGY (2015)
The genomic landscape of nasopharyngeal carcinoma
De-Chen Lin et al.
NATURE GENETICS (2014)
CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
Jorge Franco et al.
ONCOTARGET (2014)
Radioresistant Cancer Cells Can Be Conditioned to Enter Senescence by mTOR Inhibition
Hae Yun Nam et al.
CANCER RESEARCH (2013)
Bortezomib and SAHA Synergistically Induce ROS-Driven Caspase-Dependent Apoptosis of Nasopharyngeal Carcinoma and Block Replication of Epstein-Barr Virus
Kwai Fung Hui et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
Katherine Ververis et al.
BIOLOGICS-TARGETS & THERAPY (2013)
Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma
K. F. Hui et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells
Ling Cen et al.
NEURO-ONCOLOGY (2012)
Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells
Chi Man Tsang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression
Yoshiki Katsumi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
Gottfried E. Konecny et al.
CLINICAL CANCER RESEARCH (2011)
Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects
Ana-Maria Florea et al.
Cancers (2011)
edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
Mark D. Robinson et al.
BIOINFORMATICS (2010)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
J-H. Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer
Wen-Son Hsieh et al.
CLINICAL CANCER RESEARCH (2009)
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin
Melarkode S. Ramakrishnan et al.
MABS (2009)
Initial Testing (Stage 1) of Vorinostat (SAHA) by the Pediatric Preclinical Testing Program
Nino Keshelava et al.
PEDIATRIC BLOOD & CANCER (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
A novel therapeutic combination using PD 0332991 and bortezomib: Study in the 5T33MM myeloma model
Eline Menu et al.
CANCER RESEARCH (2008)
Authentication of nasopharyngeal carcinoma tumor lines
Sylvia Yat-Yee Chan et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
Discovery and development of SAHA as an anticancer agent
P. A. Marks
ONCOGENE (2007)
Molecular and cytogenetic changes involved in the immortalization of nasopharyngeal epithelial cells by telomerase
H. M. Li et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma
ABY Hui et al.
CANCER RESEARCH (2005)
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
YF Shao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes
SW Tsao et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2002)